ORCID
0009-0001-6550-298X (Olexson), 0009-0004-4995-841X (Ormaza Vera), 0009-0000-3072-6732 (Ro), 0000-0002-6783-1904 (Enos)
Document Type
Article
Publication Date
2025
DOI
10.1016/j.jdin.2025.06.006
Publication Title
JAAD International
Volume
22
Pages
88-90
Abstract
[Introduction] To the Editor: Psoriasis, an immune-mediated chronic inflammatory skin disorder, has been implicated in cognitive impairment and dementia.1, 2, 3 Emerging evidence suggests that systemic inflammation contributes to neuroinflammation and resultant cytokine-driven neurodegeneration, although findings remain inconclusive.1, 2, 3 While systemic therapies such as biologics and conventional disease-modifying antirheumatic drugs are routinely used in psoriasis management, their role in modulating dementia in this population remains underexplored, with research yielding mixed results.1, 2, 3 We conducted a large-scale, retrospective cohort study to investigate the relationship between psoriasis and dementia and whether systemic treatments for psoriasis impact this association.
Rights
© 2025 The Authors.
This is an open access article under the Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Original Publication Citation
Olexson, M. P., Ormaza Vera, A., Ro, C., & Enos, C. W. (2025). Systemic therapy targeting psoriatic inflammation is associated with decreased incidence of dementia: An observational retrospective cohort study. JAAD International, 22, 88-90. https://doi.org/10.1016/j.jdin.2025.06.006
Repository Citation
Olexson, M. P., Ormaza Vera, A., Ro, C., & Enos, C. W. (2025). Systemic therapy targeting psoriatic inflammation is associated with decreased incidence of dementia: An observational retrospective cohort study. JAAD International, 22, 88-90. https://doi.org/10.1016/j.jdin.2025.06.006
Included in
Dermatology Commons, Epidemiology Commons, Neurology Commons, Skin and Connective Tissue Diseases Commons